Iohexol Injection of Beilu Pharmaceutical Receives MA in the EU
illi News/10297920

MIYUN, China - illiNews -- Recently, Beijing Beilu Pharmaceutical Co., Ltd. received the "Marketing Authorization" (MA) issued by the Netherlands Medicines Evaluation Board (MEB) in accordance with the relevant regulations of the European Medicines Agency.

Certificate information:

• Company name: Beijing Beilu pharmaceutical Co., Ltd.
• Manufacturing address: No.3 Shuiyuan West Road, Miyun District, Beijing, China
• Registration number: RVG 132878
• Drug name: Iohexol injection 350mg(I)/ml
• Issuing authority: Netherlands Medicines Evaluation Board (MEB)

The successful registration of Iohexol Injection in Netherland indicates that the product has undergone rigorous scientific evaluation by EMA, confirming its compliance with EU Good Manufacturing Practice (GMP), quality, safety and efficacy standards. This authorization enables commercial distribution in EU-approved countries. It creates conditions for speeding up the Mutual recognition procedures(MRP) among EU countries such as Germany, France, Italy and others as well. This will help Beilu Pharmaceutical further promote the expansion of its overseas market and enhance the international market competitiveness of its contrast agent products, which is expected to have a positive impact on the company's operations in the future.

More on illi News

• Naperville: Bulk Brush Collection to Help Residents With Spring Yard Clean-Ups
• Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors
• OpenSSL Technical Advisory Committee Elections Now Open – Cast Your Vote
• RallyCap Sports Launches New Illinois Chapter: Inclusive Sports Coming to Sheridan!
• Axiros Confirms Continued Compliance with ISO/IEC 27001:2022 After Surveillance Audit

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com